In a building adjacent to the technology transfer office at Indiana University, John Hurrell is hoping to create a new kind of proteomics consortium. Unlike its counterpart in Michigan, a multi-university distributed research program funded with money from the state’s tobacco settlement, Hurrel’s Indiana Proteomics Consortium is working directly with big pharma — in the form of Eli Lilly, the fifth largest pharma company in the US.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.